recent
studi
use
radioligand
bind
show
rat
least
three
distinct
subtyp
present
wikberg
et
al
xia
et
al
follow
earlier
proposit
bylund
bylund
nomenclatur
aeadrenoceptor
rat
receptor
classifi
aeaadrenoceptor
found
kidney
spinal
cord
cerebr
cortex
kidney
neonat
lung
spinal
cord
cerebr
cortex
howev
also
found
strong
evid
rat
heterogen
could
seemingli
subdivid
two
form
term
xia
et
al
among
sever
subtypeselect
compound
guanoxabenz
shown
best
drug
differenti
aemand
aebeadrenoceptor
previou
studi
also
note
guanoxabenz
show
grossli
differ
affin
kidney
n
cerebr
cortex
rat
possibl
indic
type
heterogen
n
g
et
al
present
studi
design
character
rat
present
data
indic
rat
also
seem
exist
two
form
n
form
f
u
n
spleen
n
kidney
wherea
form
found
spleen
spinal
cord
cerebr
cortex
moreov
recent
clone
rat
gene
r
g
lanier
et
al
use
express
cell
receptor
obtain
show
properti
far
drug
capabl
distinguish
n
form
appear
guanoxabenz
affin
differ
approxim
two
form
express
cell
gene
clone
ecor
site
vector
previous
describ
lanier
et
al
plasmid
purifi
use
quiagen
kit
use
transfeet
cell
afford
transient
express
cell
grown
dulbecco
modifi
eagl
medium
fetal
calf
serum
subconflu
cultur
mm
dish
transfect
tg
plasmid
dna
tg
lipofectin
reagent
brl
usa
accord
instruct
suppli
manufactur
cell
harvest
h
transfect
prepar
membran
membran
prepar
membran
rat
spleen
kidney
spinal
cord
cerebr
cortex
prepar
spraguedawley
rat
essenti
describ
previous
wikberg
b
final
membran
fraction
dilut
give
protein
concentr
mg
proteinml
kidney
mg
proteinml
spleen
spinal
cord
cerebr
cortex
ph
cell
membran
prepar
scrape
cell
icecold
phosphat
buffer
salin
contain
edta
ph
centrifug
rain
cell
resuspend
icecold
contain
edta
phenylmethylsulphonyl
fluorid
soybean
trypsin
inhibitor
tgml
bacitracin
ph
homogen
sec
ultraturrax
rpm
homogen
spun
g
rain
final
pellet
resuspend
edta
ph
give
protein
concentr
mgml
membran
prepar
frozen
store
day
use
protein
measur
accord
lowri
et
al
bind
studi
radioligand
bind
assay
done
essenti
previous
describ
wikberg
incub
membran
solut
contain
edta
gpp
nh
p
differ
drug
h
filter
wash
whatman
gfc
filter
assay
perform
duplic
satur
experi
includ
concentr
nonspecif
bind
determin
presenc
bdf
comput
model
data
previous
describ
wikberg
c
gave
dissoci
constant
kd
drug
pkivalu
drug
calcul
kd
hill
coeffici
calcul
fit
data
four
paramet
logist
function
use
nonlinear
regress
experiment
determin
valu
given
meansem
isotop
drug
chemic
rx
n
cimmol
amersham
adrenalin
amilorid
noradrenalin
dopamin
chlorpromazin
corynanthin
prazosin
yohimbin
sigma
chemic
co
adrenalin
sterlingwinthrop
research
institut
renssela
ny
omethoxyphenyl
h
h
isoquinolindion
azepexol
formerli
known
bht
thoma
biberach
germani
benoxathian
wb
research
biochem
natick
mass
bdf
isoindolin
maleat
beiersdorf
hamburg
germani
methyl
brl
c
f
imidazol
azepin
beecham
essex
uk
clonidin
boehring
ingelheim
ingelheimrhein
germani
fla
fla
kind
gift
dr
lennart
florval
astra
sodertlj
sweden
guanfacin
guanabenz
gift
dr
clae
post
astra
sweden
guanoxabenz
lhindol
roussel
romainvil
franc
methysergid
sandoz
basel
switzerland
oxymetazolin
draeo
lund
sweden
ici
imidazol
imperi
chemic
industri
plc
macclesfield
cheshir
uk
rauwolscin
roth
karlsruh
germani
rilmenidin
servier
neuillysursein
franc
mianserin
organon
oss
holland
msd
rahway
nj
skf
sk
f
swedeland
pa
uk
quinoxalin
pfizer
sandwich
uk
wy
n
lnmethylpropanesulphonamid
wyeth
maidenhead
berk
uk
tosyl
tosyl
l
tosyl
lwll
hydroxybenzyliden
tosyl
lw
tosyl
hexyloxi
benzyliden
amino
tosyl
lt
amino
tosyl
trifluoromethyl
benzyliden
amino
tosyl
synthes
dr
ph
wang
aw
tai
tang
laboratori
one
author
ejl
describ
tai
et
al
tang
et
al
wang
et
al
quiagen
kit
quiagen
usa
lipofectin
reagent
dulbecco
modifi
eagl
medium
fetal
calf
serum
brl
usa
chemic
purchas
merck
sigma
analyt
qualiti
b
n
n
g
rx
rat
spleen
cell
membran
character
incub
differ
concentr
radioligand
absenc
presenc
bdf
latter
use
defin
nonspecif
bind
result
curv
tabl
show
pkivalu
obtain
drug
well
hill
coeffici
h
competit
curv
drug
except
guanoxabenz
yield
competit
curv
steep
monophas
show
hill
coeffici
close
uniti
comput
model
compound
show
data
fit
onesit
model
best
fit
data
twosit
model
result
margin
statist
insignific
p
reduct
sum
squar
compar
sum
squar
onesit
model
notabl
strong
agonist
adrenalin
noradrenalin
also
gave
steep
curv
resolv
onesit
fit
indic
assay
includ
edta
gpp
nh
p
na
complet
elimin
agonist
high
affin
azadrenoceptor
form
pkivalu
obtain
select
drug
oxymetazolin
brl
guanfacin
select
drug
prazosin
arc
well
azcadrenoceptor
select
compound
rauwolscin
see
wikberg
c
et
al
fulli
compat
notion
site
label
rx
rat
spleen
azaadrenoceptor
howev
competit
curv
guanoxabenz
strongli
biphas
fig
comput
model
best
twosit
fit
analysi
show
two
site
fit
result
drastic
highli
signific
p
reduct
sum
squar
compar
valu
obtain
one
site
fit
test
wherea
three
site
fit
improv
regress
analysi
thu
indic
guanoxabenz
bound
high
affin
site
kd
also
low
affin
site
kd
nmoll
differ
affin
amount
analysi
show
proport
high
affin
site
guanoxabenz
low
affin
site
n
reason
guanoxabenz
test
time
competit
curv
guanoxabenz
includ
daili
assay
compound
test
done
order
ascertain
two
form
miss
batch
membran
use
day
day
variat
result
inabl
observ
put
differ
af
competitor
log
spleen
b
kidney
c
spinal
cord
cerebr
cortex
rat
competit
curv
bind
kidney
obtain
use
rx
fix
concentr
arc
assay
spinal
cord
cortex
fix
concentr
use
line
repres
computerdrawn
best
fit
assum
ligand
bound
independ
site
accord
law
mass
action
spinal
cord
cerebr
cortex
data
fit
model
assum
one
site
present
spleen
kidney
model
use
assum
two
site
present
panel
ordin
repres
total
bind
ak
guanoxabenz
high
affin
site
spleen
b
kd
guanoxabenz
low
affinitiy
site
spleen
finiti
drug
test
bind
two
form
spleen
data
show
strongli
biphas
competit
curv
guanoxabenz
consist
present
test
summar
tabl
number
structur
analog
guanoxabenz
includ
among
compound
test
spleen
sinc
gave
monophas
competit
curv
model
best
one
site
fit
abil
guanoxabenz
distinguish
two
form
spleen
appear
uniqu
among
compound
test
one
previou
studi
wikberg
use
elabor
assay
design
obtain
simultan
bind
constant
drug
aza
azbland
present
rat
kidney
present
studi
interest
character
therefor
develop
simplifi
assay
obtain
drug
pkivalu
kidney
aaaadrenoceptor
previou
studi
show
arc
high
affin
kidney
low
affin
azaadrenoceptor
theoret
calcul
use
kdvalu
rx
arc
given
previou
paper
wikberg
indic
arc
includ
assay
bind
would
block
respect
wherea
bind
would
block
evalu
approach
obtain
competit
curv
prazosin
guanoxabenz
oxymetazolin
subtypeselect
drug
three
kidney
wikberg
use
rx
well
arc
assay
addit
full
competit
curv
arc
obtain
use
condit
fig
b
data
analyz
comput
model
found
drug
test
gave
signific
two
site
fit
p
result
indic
despit
mask
effect
interf
assay
interfer
receptor
clearli
seen
minor
tail
competit
curv
oxymetazolin
guanoxabenz
well
minor
distort
low
concentr
rang
prazosin
arc
competit
curv
fig
calcul
show
site
label
rx
correspond
full
accord
theoret
calcul
pkivalu
drug
calcul
use
form
assay
data
therefor
comput
model
two
site
fit
ensur
interfer
determin
drug
pkivalu
kidney
azaadrenoceptor
see
legend
tabl
detail
calcul
use
approach
determin
bind
constant
compound
addit
prazosin
guanoxabenz
oxymetazolin
arc
data
calcul
given
tabl
along
drug
pkivalu
determin
rat
kidney
previou
studi
use
elabor
assay
wikberg
pkivalu
guanoxabenz
oxymetazolin
prazosin
arc
obtain
use
new
approach
practic
pkivalu
obtain
previou
studi
indic
valid
new
method
seen
tabl
drug
pkivalu
obtain
kidney
virtual
obtain
rat
spleen
indic
receptor
tissu
belong
categori
howev
contrast
result
obtain
spleen
analysi
data
guanoxabenz
bind
kidney
membran
indic
guanoxabenz
bound
singl
azaadrenoceptor
site
pkivalu
practic
obtain
high
affin
site
spleen
tabl
cf
fig
b
nhydroxyguanidin
analog
bound
practic
affin
kidney
spleen
azaadrenoceptor
demonstr
guanoxabenz
uniqu
among
substanc
test
abil
differenti
two
form
azaadrenoceptor
rat
tabl
seen
tabl
drug
except
guanoxabenz
gave
pkivalu
similar
obtain
spleen
kidney
support
notion
receptor
studi
azatyp
howev
affin
guanoxabenz
spinal
cord
azaadrenoceptor
lower
obtain
receptor
kidney
moreov
affin
cord
also
lower
affin
obtain
high
affin
azaadrenoceptor
site
spleen
hand
pkivalu
guanoxabenz
interact
spinal
cord
azaadrenoceptor
close
obtain
low
affin
site
spleen
differ
drug
affin
shown
fig
competit
curv
oxymetazolin
guanoxabenz
prazosin
arc
obtain
spinal
cord
shown
fig
competit
curv
compound
obtain
kidney
shown
fig
seen
spinal
cord
competit
curv
guanoxabenz
locat
far
right
curv
indic
guanoxabenz
lowest
affin
four
drug
test
spinal
cord
kidney
howev
competit
curv
guanoxabenz
locat
far
left
prazosin
arc
competit
curv
align
right
oxymetazolin
curv
indic
guanoxabenz
almost
potent
oxymetazolin
bind
kidney
azaadrenoceptor
also
seen
fig
low
affin
compon
guanoxabenz
curv
spleen
locat
right
arc
curv
similar
result
guanoxabenz
curv
obtain
spinal
cord
fig
high
affin
compon
guanoxabenz
curv
spleen
hand
locat
right
oxymetazolin
curv
locat
guanoxabenz
curv
found
kidney
c
f
fig
b
previou
studi
wikberg
found
label
homogen
popul
azaadrenoceptor
rat
cerebr
cortex
obtain
data
comparison
also
evalu
select
drug
cerebr
cortex
preliminari
analysi
satur
curv
rx
indic
ligand
label
singl
popul
site
ka
bma
fmolmg
protein
n
data
shown
graphic
competit
curv
oxymetazolin
guanoxabenz
prazosin
arc
obtain
shown
fig
pattern
competit
curv
obtain
cortex
ident
spinal
cord
comput
model
clearli
indic
onesit
fit
appropri
describ
experiment
data
pkivalu
obtain
calcul
shown
tabl
seen
tabl
drug
pk
ivalu
obtain
cortex
close
found
spinal
cord
spinal
cord
guanoxabenz
show
lower
affin
cortex
azareceptor
kidney
azaadrenoceptor
high
affin
spleen
comput
model
satur
curv
obtain
use
rx
membran
prepar
cell
transient
express
show
ligand
bound
singl
satur
site
k
capac
fmolmg
protein
n
fig
b
moreov
scatchard
transform
satur
curv
straight
result
support
notion
label
singl
site
fig
control
experi
membran
cell
treat
show
almost
neglig
nonspecif
bind
data
shown
competit
curv
drug
obtain
use
monophas
best
model
one
site
fit
fig
competit
prazosin
guanoxabenz
obtain
use
fix
concentr
line
repres
computerdrawn
best
fit
assum
ligand
bound
singl
site
ordin
c
repres
total
bind
curv
guanoxabenz
also
monophas
also
model
best
one
site
fit
fig
c
comparison
fig
c
fig
reveal
pattern
obtain
similar
found
spinal
cord
cerebr
cortex
sinc
guanoxabenz
competit
curv
isloc
right
prazosin
arc
competit
curv
pkivalu
obtain
number
drug
encod
given
tabl
valu
close
found
differ
rat
tissu
investig
affin
guanoxabenz
rg
similar
affin
guanoxabenz
spinal
cord
cerebr
cortex
well
low
affin
azaadrenoceptor
spleen
present
studi
shown
rat
kidney
show
grossli
differ
bind
properti
guanoxabenz
compar
spinal
cord
cerebr
cortex
thu
guanoxabenz
kdvalu
kidney
wherea
kdvalu
spinal
cord
cerebr
cortex
respect
moreov
data
present
studi
show
guanoxabenz
appar
bind
two
affin
rat
spleen
k
guanoxabenz
high
affin
form
spleen
wherea
k
low
affin
form
valu
amount
approxim
differ
appar
affin
two
form
thu
appear
one
two
form
spleen
show
high
affin
guanoxabenz
similar
shown
kidney
wherea
show
low
affin
guanoxabenz
similar
shown
spinal
cord
cerebr
cortex
present
studi
also
shown
rat
clone
express
cell
produc
whose
guanoxabenz
affin
correspond
exactli
found
form
show
lower
affin
guanoxabenz
differ
tissu
investig
affin
number
drug
complet
consist
view
studi
thu
affin
select
drug
guanfacin
oxymetazolin
select
drug
prazosin
well
drug
mk
wb
rauwolscin
correspond
exactli
see
wikberg
c
et
al
contrast
affin
distinctli
differ
affin
previous
determin
wikberg
c
uhln
et
al
xia
et
al
therefor
azadrenoceptor
investig
present
studi
clearli
type
howev
data
present
studi
indic
exist
two
form
highli
differ
appar
affin
guanoxabenz
suggest
form
oper
term
form
show
high
affin
form
show
low
affin
guanoxabenz
nomenclatur
line
previou
nomenclatur
two
appar
form
rat
term
guanoxabenz
nhydroxyguanidin
seem
quit
remark
properti
enabl
differenti
present
studi
well
xia
et
al
present
studi
evalu
sever
nhydroxyguanidin
structur
analog
guanoxabenz
interestingli
none
capabl
delin
rat
subtyp
result
indic
structur
requir
select
strict
sole
depend
hydroxyguanidinium
side
chain
present
guanoxabenz
context
would
like
mention
recent
found
also
nhydroxyguanidin
use
discrimin
rat
kidney
xia
et
al
present
studi
howev
lt
fail
distinguish
ifrom
tabl
molecular
basi
appar
heterogen
among
rat
present
clear
straightforward
explan
azaadrenoc
ptor
exist
two
distinct
speci
possibl
code
differ
gene
interpret
support
observ
encod
receptor
show
properti
similar
rat
tissu
howev
possibl
also
consid
could
exampl
posttransl
modifi
lost
aquir
abil
bind
guanoxabenz
high
affin
modif
could
involv
specif
amino
acid
interact
guanoxabenz
ligand
bind
pocket
prerequisit
hypothesi
gener
structur
receptor
chang
modif
none
drug
test
capabl
point
possibl
highli
hypothet
would
support
find
condit
give
express
affin
guanoxabenz
correspond
exactli
hand
molecular
clone
distinct
novel
rat
gene
express
yield
receptor
properti
requir
prove
hypothesi
code
two
differ
gene
besid
gene
rat
number
gene
clone
gene
lanier
et
al
voigt
et
al
clearli
code
adrenoceptor
et
al
rng
gene
appear
code
adrenoceptor
zeng
et
al
thu
none
rat
gene
candid
put
gene
chalberg
cowork
clone
gene
almost
ident
albeit
minor
sequenc
differ
mean
minor
differ
present
clear
prompt
investig
present
limit
data
avail
regard
pharmacolog
properti
encod
receptor
consist
method
use
present
studi
determin
drug
affin
kidney
adrenoceptor
indic
similar
pkivalu
obtain
previou
studi
anoth
approach
use
wikberg
drug
pkivalu
subtyp
determin
present
studi
repres
agonist
bind
high
affin
form
previous
shown
spinal
cord
use
gpp
nh
p
edta
total
elimin
agonist
high
affin
bind
site
wikberg
b
moreov
data
number
tissu
indic
condit
elimin
high
affin
agonist
site
azadrenoceptor
michel
et
al
snave
insel
sinc
effect
gpp
nh
p
edta
mediat
via
gprotein
effect
na
mediat
interact
specif
aspart
residu
horstman
et
al
appear
conserv
among
gprotein
coupl
receptor
includ
clone
date
conceiv
inclus
gpp
nh
p
edta
elimin
agonist
high
affin
conform
azazadrenoceptor
sinc
result
present
studi
clearli
indic
competit
curv
strong
agonist
adrenalin
noradrenalin
fit
best
model
assum
one
site
azaadrenoceptor
clear
assay
condit
essenti
elimin
agonist
high
affin
state
thu
major
differ
appar
affin
guanoxabenz
aza
azazadrenoceptor
due
format
agonist
high
affin
state
bind
site
studi
clearli
repres
show
expect
stereoselect
bind
properti
adrenalin
affin
expect
classic
aand
azadrenoceptor
blocker
yohimbin
rauwolscin
corynanthin
prazosin
sinc
dopamin
show
much
lower
affin
either
adrenalin
noradrenalin
site
classifi
dopamin
receptor
site
label
repres
imidazolinebind
site
ireceptor
sinc
invari
show
low
nonstereoselect
affin
catecholamin
well
neglig
affin
wikberg
wikberg
wikberg
et
al
langin
et
al
context
mention
origin
classifi
lanier
et
al
pharmacolog
similar
rat
submaxillari
gland
michel
et
al
latter
place
categori
term
bylund
et
al
howev
believ
reason
abandon
nomenclatur
data
show
clearli
encod
receptor
pharmacolog
close
similar
adrenoceptor
studi
rat
classifi
origin
reason
choos
nomenclatur
receptor
among
first
rat
classifi
accord
subtyp
cerebr
cortex
azadrenoceptor
accord
origin
subtyp
classif
rat
cerebr
cortex
bylund
classifi
wikberg
b
sinc
receptor
investig
present
studi
show
pharmacolog
properti
virtual
ident
cerebr
cortex
seem
quit
logic
classifi
comparison
data
present
studi
tabl
data
report
submaxillari
gland
azi
adrenoceptor
michel
et
al
bylund
et
al
reveal
receptor
show
virtual
ident
macolog
properti
main
reason
rat
submaxillari
gland
place
categori
seem
show
fairli
low
affin
rauwolscin
yohimbin
compar
aaadrenoceptor
human
origin
earlier
classifi
type
see
bylund
et
al
michel
et
al
howev
view
fact
gene
close
similar
human
gene
encod
azadrenoceptor
human
azaadrenoceptor
profil
kobilka
et
al
harrison
et
al
b
seem
quit
reason
speci
variant
gene
therefor
present
prefer
view
azaadrenoceptor
variant
rat
correspond
human
recent
data
link
et
al
provid
strong
evid
singl
amino
acid
chang
cy
human
ser
rodent
azaadrenoceptot
respons
low
affin
yohimbin
rat
azaadrenoceptor
present
discuss
prompt
need
improv
gener
method
classif
receptor
subtyp
best
approach
futur
probabl
base
structur
receptor
summari
pertin
find
present
studi
azaadrenoceptor
rat
tissu
appear
repres
two
form
term
azat
drug
hitherto
show
major
select
two
receptor
form
guanoxabenz
present
data
combin
previou
studi
laboratori
wikberg
et
al
xia
et
al
show
least
five
form
azadrenoceptor
present
rat
azal
